Compare HCTI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCTI | BIVI |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 10.3M |
| IPO Year | 2021 | 2013 |
| Metric | HCTI | BIVI |
|---|---|---|
| Price | $0.66 | $1.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 303.0K |
| Earning Date | 04-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.83 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,891,000.00 | N/A |
| Revenue This Year | $79.33 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $0.14 | $0.82 |
| 52 Week High | $9.97 | $3.79 |
| Indicator | HCTI | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 37.66 | 40.36 |
| Support Level | $0.14 | $1.18 |
| Resistance Level | $1.01 | $1.76 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 1.24 | 1.67 |
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their efforts to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Corporate & others.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.